MannKind Corp. Stock
MannKind Corp. Stock
MannKind Corp. shows a slight decrease today, losing -€0.015 (-0.500%) compared to yesterday.
The stock is an absolute favorite of our community with 28 Buy predictions and no Sell predictions.
Based on the current price of 3.01 € the target price of 7 € shows a potential of 132.79% for MannKind Corp. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for MannKind Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of MannKind Corp. in the next few years
Pros
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of MannKind Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| MannKind Corp. | -0.500% | 25.550% | 36.065% | -29.491% | -38.727% | -15.822% | -14.391% |
| Heron Therapeutics Inc. | -0.570% | 3.235% | 54.512% | -50.424% | -5.476% | -47.871% | -92.305% |
| Evolus Inc | 0.110% | 15.568% | 50.757% | -48.757% | -3.156% | -30.553% | -28.190% |
| Sangamo Therapeutics Inc. | 50.930% | 35.092% | -41.262% | -71.434% | -56.089% | -87.325% | -98.221% |
Comments
MannKind (MNKD) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its price target raised by HC Wainwright from $8.00 to $10.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
MannKind (MNKD) had its price target lowered by Mizuho from $8.00 to $7.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for MNKD provided by MarketBeat
News
Why MannKind Stock Tumbled on Thursday
MannKind (NASDAQ: MNKD) was a stock to avoid on the second-to-last trading day of the week. Investors eagerly sold out of the commercial-stage biotech's equity, as they clearly felt its latest
Is MannKind Stock a Buy or Sell After the CEO Sold Nearly 66,000 Shares?
On Dec. 17, 2025, Michael Castagna, Chief Executive Officer of MannKind Corporation (NASDAQ:MNKD), executed an exercise and immediate sale of 65,804 common shares for a transaction value of